Vanda Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vanda Pharmaceuticals Inc. on January 30, 2007. The filing addresses Item 5.02 regarding the determination of cash incentive bonuses for Named Executive Officers (NEOs) for the fiscal year ended December 31, 2006. These amounts were not included in the company's previously filed Form S-1 Registration Statement because the Board of Directors had not finalized the figures at that time.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation data for the year ended December 31, 2006.
| Named Executive Officer | 2006 Cash Incentive Bonus | Total 2006 Compensation |
|---|---|---|
| Mihael H. Polymeropoulos, M.D. (CEO) | $250,000 | $3,609,081 |
| Paolo Baroldi, M.D., Ph.D. (SVP, CMO) | $93,750 | $413,482 |
| William D. "Chip" Clark (SVP, CBO) | $118,000 | $1,850,232 |
| Steven A. Shallcross (SVP, CFO) | $93,750 | $935,969 |
| Thomas Copmann, Ph.D. (VP, Regulatory) | $40,768 | $390,561 |
| Deepak Phadke, Ph.D. (VP, Manufacturing) | $36,465 | $343,333 |
Note: Total compensation includes salary, option awards (calculated per SFAS 123(R)), non-equity incentive plan compensation, and all other compensation.
Material Changes
The primary material change reported is the finalization of cash incentive bonuses for the 2006 fiscal year, which were previously undetermined. Additionally, the filing notes that Dr. Paolo Baroldi joined the company in July 2006, and his compensation reflects a partial year of service.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. It is a procedural disclosure to update the Summary Compensation Table.
Key Facts for Investor Verification
- Verify the total 2006 compensation figures for executives, noting that a significant portion for the CEO and other officers consists of option awards valued under SFAS 123(R).
- Confirm that the cash incentive bonuses listed were determined by the Board on January 30, 2007, and were not included in the original Form S-1 filing.
- Note that Dr. Baroldi's "All Other Compensation" includes $49,934 in relocation expenses and $12,747 in tax costs related to relocation.
- Understand that this filing does not provide updated financial performance data (revenue, cash, etc.) for the company.